nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroxyaluminium—VDAC2—renal system—kidney cancer	0.0313	0.0827	CbGeAlD
Dihydroxyaluminium—VDAC2—kidney—kidney cancer	0.0302	0.0799	CbGeAlD
Dihydroxyaluminium—VDAC3—nephron tubule—kidney cancer	0.0286	0.0758	CbGeAlD
Dihydroxyaluminium—VDAC2—gonad—kidney cancer	0.028	0.0742	CbGeAlD
Dihydroxyaluminium—VDAC1—nephron tubule—kidney cancer	0.0272	0.0721	CbGeAlD
Dihydroxyaluminium—VDAC3—renal system—kidney cancer	0.026	0.0689	CbGeAlD
Dihydroxyaluminium—VDAC1—renal system—kidney cancer	0.0248	0.0655	CbGeAlD
Dihydroxyaluminium—VDAC3—cortex of kidney—kidney cancer	0.0245	0.0649	CbGeAlD
Dihydroxyaluminium—VDAC1—Mitochondrial protein import—HSPA9—kidney cancer	0.0245	0.29	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—kidney—kidney cancer	0.0239	0.0633	CbGeAlD
Dihydroxyaluminium—VDAC3—gonad—kidney cancer	0.0233	0.0618	CbGeAlD
Dihydroxyaluminium—VDAC3—cardiac atrium—kidney cancer	0.0233	0.0617	CbGeAlD
Dihydroxyaluminium—VDAC1—cortex of kidney—kidney cancer	0.0233	0.0617	CbGeAlD
Dihydroxyaluminium—VDAC1—gonad—kidney cancer	0.0222	0.0588	CbGeAlD
Dihydroxyaluminium—VDAC1—cardiac atrium—kidney cancer	0.0222	0.0587	CbGeAlD
Dihydroxyaluminium—VDAC1—Temsirolimus—Everolimus—kidney cancer	0.0221	1	CbGdCrCtD
Dihydroxyaluminium—TNNC1—cardiac atrium—kidney cancer	0.019	0.0503	CbGeAlD
Dihydroxyaluminium—Venous thrombosis—Temsirolimus—kidney cancer	0.0148	0.0288	CcSEcCtD
Dihydroxyaluminium—VDAC1—Mitochondrial protein import—HSPD1—kidney cancer	0.0132	0.156	CbGpPWpGaD
Dihydroxyaluminium—Encephalopathy—Pazopanib—kidney cancer	0.0118	0.0228	CcSEcCtD
Dihydroxyaluminium—Lung disorder—Temsirolimus—kidney cancer	0.0113	0.022	CcSEcCtD
Dihydroxyaluminium—Acidosis—Everolimus—kidney cancer	0.0108	0.0209	CcSEcCtD
Dihydroxyaluminium—Extravasation—Temsirolimus—kidney cancer	0.00918	0.0178	CcSEcCtD
Dihydroxyaluminium—Lung disorder—Erlotinib—kidney cancer	0.00812	0.0158	CcSEcCtD
Dihydroxyaluminium—Electrolyte imbalance—Paclitaxel—kidney cancer	0.008	0.0155	CcSEcCtD
Dihydroxyaluminium—TNNC1—Muscle contraction—CALD1—kidney cancer	0.00751	0.0888	CbGpPWpGaD
Dihydroxyaluminium—Extravasation—Vinblastine—kidney cancer	0.00686	0.0133	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Temsirolimus—kidney cancer	0.00672	0.013	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Erlotinib—kidney cancer	0.00654	0.0127	CcSEcCtD
Dihydroxyaluminium—Venous thrombosis—Paclitaxel—kidney cancer	0.00619	0.012	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Pazopanib—kidney cancer	0.0055	0.0107	CcSEcCtD
Dihydroxyaluminium—Dehydration—Temsirolimus—kidney cancer	0.00541	0.0105	CcSEcCtD
Dihydroxyaluminium—Extravasation—Dactinomycin—kidney cancer	0.0054	0.0105	CcSEcCtD
Dihydroxyaluminium—Encephalopathy—Paclitaxel—kidney cancer	0.00521	0.0101	CcSEcCtD
Dihydroxyaluminium—Dehydration—Pazopanib—kidney cancer	0.00509	0.00988	CcSEcCtD
Dihydroxyaluminium—Venous thrombosis—Capecitabine—kidney cancer	0.00508	0.00986	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Vinblastine—kidney cancer	0.00504	0.00978	CcSEcCtD
Dihydroxyaluminium—Polyuria—Everolimus—kidney cancer	0.00493	0.00956	CcSEcCtD
Dihydroxyaluminium—Extravasation—Vincristine—kidney cancer	0.00482	0.00936	CcSEcCtD
Dihydroxyaluminium—Extravasation—Gemcitabine—kidney cancer	0.00458	0.00888	CcSEcCtD
Dihydroxyaluminium—TNNC1—MFAP5-mediated ovarian cancer cell motility and invasiveness—JUN—kidney cancer	0.00455	0.0537	CbGpPWpGaD
Dihydroxyaluminium—Hyponatraemia—Everolimus—kidney cancer	0.00434	0.00843	CcSEcCtD
Dihydroxyaluminium—Encephalopathy—Capecitabine—kidney cancer	0.00427	0.00829	CcSEcCtD
Dihydroxyaluminium—Urinary retention—Everolimus—kidney cancer	0.00411	0.00798	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Temsirolimus—kidney cancer	0.00403	0.00782	CcSEcCtD
Dihydroxyaluminium—Dehydration—Everolimus—kidney cancer	0.00402	0.0078	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Dactinomycin—kidney cancer	0.00397	0.0077	CcSEcCtD
Dihydroxyaluminium—Dehydration—Erlotinib—kidney cancer	0.00388	0.00753	CcSEcCtD
Dihydroxyaluminium—Coma—Vincristine—kidney cancer	0.00385	0.00746	CcSEcCtD
Dihydroxyaluminium—Extravasation—Paclitaxel—kidney cancer	0.00383	0.00744	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Sorafenib—kidney cancer	0.00377	0.00731	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—EIF5B—kidney cancer	0.00367	0.0434	CbGpPWpGaD
Dihydroxyaluminium—Angina pectoris—Vinblastine—kidney cancer	0.00366	0.00709	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Everolimus—kidney cancer	0.00364	0.00707	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Sunitinib—kidney cancer	0.00363	0.00704	CcSEcCtD
Dihydroxyaluminium—Chills—Temsirolimus—kidney cancer	0.00361	0.007	CcSEcCtD
Dihydroxyaluminium—TNNC1—MFAP5-mediated ovarian cancer cell motility and invasiveness—MAPK1—kidney cancer	0.00358	0.0423	CbGpPWpGaD
Dihydroxyaluminium—Dehydration—Sorafenib—kidney cancer	0.00349	0.00677	CcSEcCtD
Dihydroxyaluminium—Polyuria—Vincristine—kidney cancer	0.00348	0.00675	CcSEcCtD
Dihydroxyaluminium—Chills—Pazopanib—kidney cancer	0.0034	0.0066	CcSEcCtD
Dihydroxyaluminium—Back pain—Temsirolimus—kidney cancer	0.00339	0.00657	CcSEcCtD
Dihydroxyaluminium—Dehydration—Sunitinib—kidney cancer	0.00336	0.00652	CcSEcCtD
Dihydroxyaluminium—Venous thrombosis—Doxorubicin—kidney cancer	0.00328	0.00636	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—CUL7—kidney cancer	0.00327	0.0387	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—HSPA9—kidney cancer	0.00312	0.0369	CbGpPWpGaD
Dihydroxyaluminium—Vision blurred—Pazopanib—kidney cancer	0.00311	0.00603	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Vincristine—kidney cancer	0.00307	0.00595	CcSEcCtD
Dihydroxyaluminium—Convulsion—Temsirolimus—kidney cancer	0.00303	0.00589	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Everolimus—kidney cancer	0.003	0.00582	CcSEcCtD
Dihydroxyaluminium—Lightheadedness—Paclitaxel—kidney cancer	0.00299	0.0058	CcSEcCtD
Dihydroxyaluminium—Urinary retention—Vincristine—kidney cancer	0.00291	0.00564	CcSEcCtD
Dihydroxyaluminium—Oedema—Temsirolimus—kidney cancer	0.00286	0.00555	CcSEcCtD
Dihydroxyaluminium—Dehydration—Vincristine—kidney cancer	0.00284	0.00551	CcSEcCtD
Dihydroxyaluminium—Infection—Temsirolimus—kidney cancer	0.00284	0.00551	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Paclitaxel—kidney cancer	0.00282	0.00547	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Paclitaxel—kidney cancer	0.0028	0.00544	CcSEcCtD
Dihydroxyaluminium—Polyuria—Paclitaxel—kidney cancer	0.00276	0.00536	CcSEcCtD
Dihydroxyaluminium—Oedema—Pazopanib—kidney cancer	0.00269	0.00522	CcSEcCtD
Dihydroxyaluminium—Chills—Everolimus—kidney cancer	0.00268	0.00521	CcSEcCtD
Dihydroxyaluminium—Infection—Pazopanib—kidney cancer	0.00267	0.00519	CcSEcCtD
Dihydroxyaluminium—Chills—Erlotinib—kidney cancer	0.00259	0.00503	CcSEcCtD
Dihydroxyaluminium—Visual disturbance—Paclitaxel—kidney cancer	0.00256	0.00497	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—MUC4—kidney cancer	0.00255	0.0301	CbGpPWpGaD
Dihydroxyaluminium—Back pain—Everolimus—kidney cancer	0.00252	0.00489	CcSEcCtD
Dihydroxyaluminium—Lung disorder—Doxorubicin—kidney cancer	0.0025	0.00485	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Everolimus—kidney cancer	0.00245	0.00476	CcSEcCtD
Dihydroxyaluminium—Pain—Temsirolimus—kidney cancer	0.00244	0.00474	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Paclitaxel—kidney cancer	0.00244	0.00473	CcSEcCtD
Dihydroxyaluminium—Back pain—Erlotinib—kidney cancer	0.00243	0.00472	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—ST3GAL2—kidney cancer	0.00242	0.0286	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—EEF2—kidney cancer	0.00237	0.028	CbGpPWpGaD
Dihydroxyaluminium—Vertigo—Vinblastine—kidney cancer	0.00235	0.00456	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Capecitabine—kidney cancer	0.00231	0.00449	CcSEcCtD
Dihydroxyaluminium—Pain—Pazopanib—kidney cancer	0.0023	0.00447	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Capecitabine—kidney cancer	0.0023	0.00446	CcSEcCtD
Dihydroxyaluminium—Polyuria—Capecitabine—kidney cancer	0.00227	0.0044	CcSEcCtD
Dihydroxyaluminium—Convulsion—Vinblastine—kidney cancer	0.00227	0.0044	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Temsirolimus—kidney cancer	0.00226	0.00438	CcSEcCtD
Dihydroxyaluminium—Dehydration—Paclitaxel—kidney cancer	0.00226	0.00438	CcSEcCtD
Dihydroxyaluminium—Convulsion—Everolimus—kidney cancer	0.00226	0.00438	CcSEcCtD
Dihydroxyaluminium—Chills—Sunitinib—kidney cancer	0.00224	0.00435	CcSEcCtD
Dihydroxyaluminium—Oedema—Everolimus—kidney cancer	0.00213	0.00412	CcSEcCtD
Dihydroxyaluminium—Chills—Dactinomycin—kidney cancer	0.00212	0.00412	CcSEcCtD
Dihydroxyaluminium—Infection—Everolimus—kidney cancer	0.00211	0.0041	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Temsirolimus—kidney cancer	0.00211	0.00409	CcSEcCtD
Dihydroxyaluminium—Back pain—Sunitinib—kidney cancer	0.0021	0.00408	CcSEcCtD
Dihydroxyaluminium—Thirst—Capecitabine—kidney cancer	0.00209	0.00406	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Everolimus—kidney cancer	0.00207	0.00403	CcSEcCtD
Dihydroxyaluminium—Oedema—Erlotinib—kidney cancer	0.00205	0.00398	CcSEcCtD
Dihydroxyaluminium—Infection—Erlotinib—kidney cancer	0.00204	0.00395	CcSEcCtD
Dihydroxyaluminium—Extravasation—Doxorubicin—kidney cancer	0.00203	0.00393	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Doxorubicin—kidney cancer	0.00201	0.00391	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Gemcitabine—kidney cancer	0.00201	0.0039	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Capecitabine—kidney cancer	0.002	0.00388	CcSEcCtD
Dihydroxyaluminium—Hypotension—Everolimus—kidney cancer	0.00199	0.00385	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Temsirolimus—kidney cancer	0.00196	0.00379	CcSEcCtD
Dihydroxyaluminium—Urinary retention—Capecitabine—kidney cancer	0.00189	0.00367	CcSEcCtD
Dihydroxyaluminium—Dizziness—Temsirolimus—kidney cancer	0.00189	0.00367	CcSEcCtD
Dihydroxyaluminium—Convulsion—Sunitinib—kidney cancer	0.00188	0.00366	CcSEcCtD
Dihydroxyaluminium—Dehydration—Capecitabine—kidney cancer	0.00185	0.00359	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Pazopanib—kidney cancer	0.00184	0.00357	CcSEcCtD
Dihydroxyaluminium—Infection—Sorafenib—kidney cancer	0.00183	0.00356	CcSEcCtD
Dihydroxyaluminium—Pain—Vinblastine—kidney cancer	0.00182	0.00354	CcSEcCtD
Dihydroxyaluminium—Pain—Everolimus—kidney cancer	0.00182	0.00353	CcSEcCtD
Dihydroxyaluminium—Vomiting—Temsirolimus—kidney cancer	0.00182	0.00353	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—MME—kidney cancer	0.00181	0.0214	CbGpPWpGaD
Dihydroxyaluminium—Chills—Gemcitabine—kidney cancer	0.0018	0.00349	CcSEcCtD
Dihydroxyaluminium—Dizziness—Pazopanib—kidney cancer	0.00178	0.00345	CcSEcCtD
Dihydroxyaluminium—Back pain—Vincristine—kidney cancer	0.00178	0.00345	CcSEcCtD
Dihydroxyaluminium—Oedema—Sunitinib—kidney cancer	0.00178	0.00345	CcSEcCtD
Dihydroxyaluminium—Infection—Sunitinib—kidney cancer	0.00176	0.00342	CcSEcCtD
Dihydroxyaluminium—Pain—Erlotinib—kidney cancer	0.00175	0.0034	CcSEcCtD
Dihydroxyaluminium—Salivary hypersecretion—Doxorubicin—kidney cancer	0.00172	0.00333	CcSEcCtD
Dihydroxyaluminium—Vomiting—Pazopanib—kidney cancer	0.00171	0.00332	CcSEcCtD
Dihydroxyaluminium—Nausea—Temsirolimus—kidney cancer	0.0017	0.00329	CcSEcCtD
Dihydroxyaluminium—Back pain—Gemcitabine—kidney cancer	0.00169	0.00328	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—HSPD1—kidney cancer	0.00169	0.0199	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—RPL14—kidney cancer	0.00169	0.0199	CbGpPWpGaD
Dihydroxyaluminium—Rhinitis—Paclitaxel—kidney cancer	0.00168	0.00327	CcSEcCtD
Dihydroxyaluminium—Oedema—Dactinomycin—kidney cancer	0.00168	0.00326	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Everolimus—kidney cancer	0.00168	0.00326	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Capecitabine—kidney cancer	0.00168	0.00325	CcSEcCtD
Dihydroxyaluminium—Infection—Dactinomycin—kidney cancer	0.00167	0.00324	CcSEcCtD
Dihydroxyaluminium—Vertigo—Vincristine—kidney cancer	0.00165	0.00321	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Erlotinib—kidney cancer	0.00162	0.00315	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Paclitaxel—kidney cancer	0.00162	0.00314	CcSEcCtD
Dihydroxyaluminium—Coma—Doxorubicin—kidney cancer	0.00162	0.00314	CcSEcCtD
Dihydroxyaluminium—Nausea—Pazopanib—kidney cancer	0.0016	0.0031	CcSEcCtD
Dihydroxyaluminium—Convulsion—Vincristine—kidney cancer	0.00159	0.00309	CcSEcCtD
Dihydroxyaluminium—Pain—Sorafenib—kidney cancer	0.00158	0.00306	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Vinblastine—kidney cancer	0.00157	0.00305	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Everolimus—kidney cancer	0.00157	0.00304	CcSEcCtD
Dihydroxyaluminium—Pain—Sunitinib—kidney cancer	0.00152	0.00295	CcSEcCtD
Dihydroxyaluminium—Chills—Paclitaxel—kidney cancer	0.00151	0.00292	CcSEcCtD
Dihydroxyaluminium—Oedema—Vincristine—kidney cancer	0.0015	0.00291	CcSEcCtD
Dihydroxyaluminium—Infection—Vincristine—kidney cancer	0.00149	0.0029	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Doxorubicin—kidney cancer	0.00149	0.00289	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Doxorubicin—kidney cancer	0.00148	0.00288	CcSEcCtD
Dihydroxyaluminium—Urticaria—Sorafenib—kidney cancer	0.00147	0.00284	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Vinblastine—kidney cancer	0.00146	0.00283	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Sorafenib—kidney cancer	0.00146	0.00283	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Everolimus—kidney cancer	0.00145	0.00282	CcSEcCtD
Dihydroxyaluminium—Pain—Dactinomycin—kidney cancer	0.00144	0.00279	CcSEcCtD
Dihydroxyaluminium—Oedema—Gemcitabine—kidney cancer	0.00142	0.00276	CcSEcCtD
Dihydroxyaluminium—Infection—Gemcitabine—kidney cancer	0.00142	0.00275	CcSEcCtD
Dihydroxyaluminium—Back pain—Paclitaxel—kidney cancer	0.00141	0.00274	CcSEcCtD
Dihydroxyaluminium—Dizziness—Vinblastine—kidney cancer	0.00141	0.00274	CcSEcCtD
Dihydroxyaluminium—Dizziness—Everolimus—kidney cancer	0.00141	0.00273	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Sunitinib—kidney cancer	0.0014	0.00272	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Erlotinib—kidney cancer	0.0014	0.00272	CcSEcCtD
Dihydroxyaluminium—Hypotension—Vincristine—kidney cancer	0.0014	0.00272	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—ACHE—kidney cancer	0.00139	0.0164	CbGpPWpGaD
Dihydroxyaluminium—Rhinitis—Capecitabine—kidney cancer	0.00138	0.00268	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Paclitaxel—kidney cancer	0.00138	0.00267	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—EIF4EBP1—kidney cancer	0.00137	0.0163	CbGpPWpGaD
Dihydroxyaluminium—Hypersensitivity—Sorafenib—kidney cancer	0.00136	0.00264	CcSEcCtD
Dihydroxyaluminium—Vomiting—Vinblastine—kidney cancer	0.00136	0.00263	CcSEcCtD
Dihydroxyaluminium—Dizziness—Erlotinib—kidney cancer	0.00136	0.00263	CcSEcCtD
Dihydroxyaluminium—Vomiting—Everolimus—kidney cancer	0.00135	0.00262	CcSEcCtD
Dihydroxyaluminium—Hypotension—Gemcitabine—kidney cancer	0.00133	0.00258	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Dactinomycin—kidney cancer	0.00133	0.00258	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Capecitabine—kidney cancer	0.00133	0.00258	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—PAX6—kidney cancer	0.00132	0.0156	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—CTSD—kidney cancer	0.00132	0.0156	CbGpPWpGaD
Dihydroxyaluminium—Vertigo—Paclitaxel—kidney cancer	0.00131	0.00255	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Sunitinib—kidney cancer	0.00131	0.00254	CcSEcCtD
Dihydroxyaluminium—Vomiting—Erlotinib—kidney cancer	0.0013	0.00253	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Doxorubicin—kidney cancer	0.00129	0.0025	CcSEcCtD
Dihydroxyaluminium—Pain—Vincristine—kidney cancer	0.00128	0.00249	CcSEcCtD
Dihydroxyaluminium—Nausea—Vinblastine—kidney cancer	0.00127	0.00246	CcSEcCtD
Dihydroxyaluminium—Convulsion—Paclitaxel—kidney cancer	0.00127	0.00246	CcSEcCtD
Dihydroxyaluminium—Nausea—Everolimus—kidney cancer	0.00126	0.00245	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Sorafenib—kidney cancer	0.00126	0.00245	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Dactinomycin—kidney cancer	0.00124	0.0024	CcSEcCtD
Dihydroxyaluminium—Chills—Capecitabine—kidney cancer	0.00124	0.0024	CcSEcCtD
Dihydroxyaluminium—Dizziness—Sorafenib—kidney cancer	0.00122	0.00237	CcSEcCtD
Dihydroxyaluminium—Pain—Gemcitabine—kidney cancer	0.00122	0.00236	CcSEcCtD
Dihydroxyaluminium—Nausea—Erlotinib—kidney cancer	0.00122	0.00236	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Sunitinib—kidney cancer	0.00121	0.00236	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—BCHE—kidney cancer	0.00121	0.0143	CbGpPWpGaD
Dihydroxyaluminium—Dehydration—Doxorubicin—kidney cancer	0.00119	0.00232	CcSEcCtD
Dihydroxyaluminium—Oedema—Paclitaxel—kidney cancer	0.00119	0.00231	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Vincristine—kidney cancer	0.00119	0.0023	CcSEcCtD
Dihydroxyaluminium—Infection—Paclitaxel—kidney cancer	0.00119	0.0023	CcSEcCtD
Dihydroxyaluminium—Dizziness—Sunitinib—kidney cancer	0.00117	0.00228	CcSEcCtD
Dihydroxyaluminium—Vomiting—Sorafenib—kidney cancer	0.00117	0.00228	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Paclitaxel—kidney cancer	0.00116	0.00226	CcSEcCtD
Dihydroxyaluminium—Back pain—Capecitabine—kidney cancer	0.00116	0.00225	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Dactinomycin—kidney cancer	0.00115	0.00223	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Capecitabine—kidney cancer	0.00113	0.00219	CcSEcCtD
Dihydroxyaluminium—Vomiting—Sunitinib—kidney cancer	0.00113	0.00219	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Gemcitabine—kidney cancer	0.00113	0.00219	CcSEcCtD
Dihydroxyaluminium—Hypotension—Paclitaxel—kidney cancer	0.00111	0.00216	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Vincristine—kidney cancer	0.00111	0.00215	CcSEcCtD
Dihydroxyaluminium—Nausea—Sorafenib—kidney cancer	0.0011	0.00213	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Doxorubicin—kidney cancer	0.00108	0.0021	CcSEcCtD
Dihydroxyaluminium—Vertigo—Capecitabine—kidney cancer	0.00108	0.00209	CcSEcCtD
Dihydroxyaluminium—Vomiting—Dactinomycin—kidney cancer	0.00107	0.00207	CcSEcCtD
Dihydroxyaluminium—Nausea—Sunitinib—kidney cancer	0.00105	0.00205	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Vincristine—kidney cancer	0.00103	0.00199	CcSEcCtD
Dihydroxyaluminium—Pain—Paclitaxel—kidney cancer	0.00102	0.00198	CcSEcCtD
Dihydroxyaluminium—Nausea—Dactinomycin—kidney cancer	0.000998	0.00194	CcSEcCtD
Dihydroxyaluminium—Dizziness—Vincristine—kidney cancer	0.000993	0.00193	CcSEcCtD
Dihydroxyaluminium—Oedema—Capecitabine—kidney cancer	0.000979	0.0019	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Gemcitabine—kidney cancer	0.000975	0.00189	CcSEcCtD
Dihydroxyaluminium—Infection—Capecitabine—kidney cancer	0.000972	0.00189	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Capecitabine—kidney cancer	0.000955	0.00185	CcSEcCtD
Dihydroxyaluminium—Vomiting—Vincristine—kidney cancer	0.000955	0.00185	CcSEcCtD
Dihydroxyaluminium—Urticaria—Paclitaxel—kidney cancer	0.000948	0.00184	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Paclitaxel—kidney cancer	0.000943	0.00183	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—IGF2—kidney cancer	0.000938	0.0111	CbGpPWpGaD
Dihydroxyaluminium—Hypotension—Capecitabine—kidney cancer	0.000915	0.00177	CcSEcCtD
Dihydroxyaluminium—Vomiting—Gemcitabine—kidney cancer	0.000906	0.00176	CcSEcCtD
Dihydroxyaluminium—Nausea—Vincristine—kidney cancer	0.000892	0.00173	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Doxorubicin—kidney cancer	0.00089	0.00173	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Paclitaxel—kidney cancer	0.000879	0.00171	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Doxorubicin—kidney cancer	0.000856	0.00166	CcSEcCtD
Dihydroxyaluminium—Nausea—Gemcitabine—kidney cancer	0.000846	0.00164	CcSEcCtD
Dihydroxyaluminium—Pain—Capecitabine—kidney cancer	0.000837	0.00162	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Paclitaxel—kidney cancer	0.000816	0.00158	CcSEcCtD
Dihydroxyaluminium—Chills—Doxorubicin—kidney cancer	0.000797	0.00155	CcSEcCtD
Dihydroxyaluminium—Dizziness—Paclitaxel—kidney cancer	0.000789	0.00153	CcSEcCtD
Dihydroxyaluminium—Urticaria—Capecitabine—kidney cancer	0.000778	0.00151	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Capecitabine—kidney cancer	0.000774	0.0015	CcSEcCtD
Dihydroxyaluminium—Vomiting—Paclitaxel—kidney cancer	0.000758	0.00147	CcSEcCtD
Dihydroxyaluminium—Back pain—Doxorubicin—kidney cancer	0.000748	0.00145	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Doxorubicin—kidney cancer	0.000729	0.00141	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Capecitabine—kidney cancer	0.000721	0.0014	CcSEcCtD
Dihydroxyaluminium—Nausea—Paclitaxel—kidney cancer	0.000709	0.00137	CcSEcCtD
Dihydroxyaluminium—Vertigo—Doxorubicin—kidney cancer	0.000695	0.00135	CcSEcCtD
Dihydroxyaluminium—Convulsion—Doxorubicin—kidney cancer	0.00067	0.0013	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Capecitabine—kidney cancer	0.00067	0.0013	CcSEcCtD
Dihydroxyaluminium—Dizziness—Capecitabine—kidney cancer	0.000647	0.00126	CcSEcCtD
Dihydroxyaluminium—Oedema—Doxorubicin—kidney cancer	0.000631	0.00122	CcSEcCtD
Dihydroxyaluminium—Infection—Doxorubicin—kidney cancer	0.000627	0.00122	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—POMC—kidney cancer	0.000626	0.0074	CbGpPWpGaD
Dihydroxyaluminium—Vomiting—Capecitabine—kidney cancer	0.000622	0.00121	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Doxorubicin—kidney cancer	0.000616	0.00119	CcSEcCtD
Dihydroxyaluminium—Hypotension—Doxorubicin—kidney cancer	0.00059	0.00114	CcSEcCtD
Dihydroxyaluminium—Nausea—Capecitabine—kidney cancer	0.000581	0.00113	CcSEcCtD
Dihydroxyaluminium—Pain—Doxorubicin—kidney cancer	0.00054	0.00105	CcSEcCtD
Dihydroxyaluminium—Urticaria—Doxorubicin—kidney cancer	0.000501	0.000973	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Doxorubicin—kidney cancer	0.000499	0.000968	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Doxorubicin—kidney cancer	0.000465	0.000902	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—CTNNB1—kidney cancer	0.000447	0.00528	CbGpPWpGaD
Dihydroxyaluminium—Diarrhoea—Doxorubicin—kidney cancer	0.000432	0.000838	CcSEcCtD
Dihydroxyaluminium—Dizziness—Doxorubicin—kidney cancer	0.000417	0.00081	CcSEcCtD
Dihydroxyaluminium—Vomiting—Doxorubicin—kidney cancer	0.000401	0.000778	CcSEcCtD
Dihydroxyaluminium—Nausea—Doxorubicin—kidney cancer	0.000375	0.000727	CcSEcCtD
